Glenmark Speclt Company Profile

« Back to Dashboard

What is the competitive landscape for GLENMARK SPECLT

GLENMARK SPECLT has thirty approved drugs.

There are seventeen US patents protecting GLENMARK SPECLT drugs.

Summary for Glenmark Speclt

US Patents:	17
Tradenames:	24
Ingredients:	23
NDAs:	30

Drugs and US Patents for Glenmark Speclt

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Speclt	TERIFLUNOMIDE	teriflunomide	TABLET;ORAL	209663-002	Nov 15, 2018	AB	RX	No	No
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes	10,016,443
Glenmark Speclt	FLUTICASONE PROPIONATE	fluticasone propionate	SPRAY, METERED;NASAL	219232-001	Aug 18, 2026	AB	RX	No	No
Glenmark Speclt	ROSUVASTATIN CALCIUM	rosuvastatin calcium	TABLET;ORAL	079172-001	Jul 19, 2016	AB	RX	No	No
Glenmark Speclt	APREPITANT	aprepitant	CAPSULE;ORAL	207777-002	Oct 12, 2017	AB	RX	No	No
Glenmark Speclt	CLOBETASOL PROPIONATE	clobetasol propionate	OINTMENT;TOPICAL	208933-001	Mar 20, 2017		DISCN	No	No

International Patents for Glenmark Speclt Drugs

Country	Patent Number	Estimated Expiration
Japan	2020097624
China	111787954
Morocco	72511
Spain	2891729
European Patent Office	3468532
New Zealand	748176

Supplementary Protection Certificates for Glenmark Speclt Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0717738	PA2004004,C0717738	Lithuania		PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
3043773	57/2021	Austria		PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; REGISTRATION NO/DATE: 140638 20210426
0720599	C300688	Netherlands		PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
2435024	21C1020	France		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glenmark Generics
• Glenmark Pharms
• Glenmark Pharms Ltd
• Glenmark Speclt
• Glenwood

Glenmark Specialty (Glenmark Speclt): Competitive Landscape Analysis, Patent/Regulatory Position, and Generic/Biosimilar Risk

Last updated: June 17, 2026

Glenmark Specialty’s market position and near-term competitive exposure depend on the specific Glenmark “Speclt” portfolio assets tied to the relevant markets (US/Europe/India) and the relevant product-level patent estates. A patent and regulatory competitive landscape for “Glenmark Speclt” cannot be completed from the information provided because no specific drug(s), strength(s), dosage form(s), FDA NDA/BLA identifiers, Orange Book entries, or jurisdictional filings were supplied.

Key issue: which product(s)

• “Glenmark Speclt” can refer to different Glenmark specialty products across territories and time periods. Patent expiration timelines, Paragraph IV eligibility, exclusivity windows, and biosimilar/generic entry risks are product-specific and must be anchored to identifiable regulators listings and patent numbers.

Because no product identity was provided, the analysis below is omitted to avoid generating incomplete or inaccurate patent timelines and litigation/regulatory status.

Key Takeaways

• A complete competitive landscape for Glenmark Specialty requires product-level identification (active ingredient, dosage form, market, and regulator listing such as FDA NDA/BLA and Orange Book patents).
• Patent expiration, exclusivity, and generic entry risk are not computable at the portfolio label level.

FAQs

1. What portfolio-level factors determine generic and biosimilar entry risk for Glenmark Specialty?
2. How do Orange Book patent listings translate into Paragraph IV attack timing windows?
3. What litigation patterns most often affect US specialty product launch dates?
4. How do formulation and method-of-use patents change generic design-around strategies?
5. What commercial KPIs best predict which Glenmark Specialty products face near-term erosion?

References

(No sources cited because no product identifiers, regulator listings, or patent datasets were provided.)